Logo image of KMDA

KAMADA LTD (KMDA) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:KMDA - IL0010941198 - Common Stock

7.07 USD
-0.02 (-0.28%)
Last: 12/26/2025, 8:00:02 PM
Fundamental Rating

6

We assign a fundamental rating of 6 out of 10 to KMDA. KMDA was compared to 530 industry peers in the Biotechnology industry. While KMDA belongs to the best of the industry regarding profitability, there are some minor concerns on its financial health. KMDA may be a bit undervalued, certainly considering the very reasonable score on growth This makes KMDA very considerable for value investing!


Dividend Valuation Growth Profitability Health

7

1. Profitability

1.1 Basic Checks

KMDA had positive earnings in the past year.
KMDA had a positive operating cash flow in the past year.
The reported net income has been mixed in the past 5 years: KMDA reported negative net income in multiple years.
KMDA had a positive operating cash flow in 4 of the past 5 years.
KMDA Yearly Net Income VS EBIT VS OCF VS FCFKMDA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M 40M

1.2 Ratios

KMDA has a Return On Assets of 5.42%. This is amongst the best in the industry. KMDA outperforms 91.70% of its industry peers.
KMDA has a Return On Equity of 7.72%. This is amongst the best in the industry. KMDA outperforms 91.51% of its industry peers.
Looking at the Return On Invested Capital, with a value of 6.67%, KMDA belongs to the top of the industry, outperforming 92.83% of the companies in the same industry.
Measured over the past 3 years, the Average Return On Invested Capital for KMDA is significantly below the industry average of 18.22%.
The 3 year average ROIC (2.97%) for KMDA is below the current ROIC(6.67%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 5.42%
ROE 7.72%
ROIC 6.67%
ROA(3y)1.79%
ROA(5y)2.56%
ROE(3y)2.5%
ROE(5y)3.16%
ROIC(3y)2.97%
ROIC(5y)N/A
KMDA Yearly ROA, ROE, ROICKMDA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10 -10

1.3 Margins

The Profit Margin of KMDA (11.70%) is better than 91.70% of its industry peers.
KMDA's Profit Margin has declined in the last couple of years.
KMDA has a Operating Margin of 15.89%. This is amongst the best in the industry. KMDA outperforms 93.58% of its industry peers.
In the last couple of years the Operating Margin of KMDA has declined.
KMDA has a Gross Margin of 43.75%. This is in the better half of the industry: KMDA outperforms 74.53% of its industry peers.
In the last couple of years the Gross Margin of KMDA has grown nicely.
Industry RankSector Rank
OM 15.89%
PM (TTM) 11.7%
GM 43.75%
OM growth 3YN/A
OM growth 5Y-7.07%
PM growth 3YN/A
PM growth 5Y-13.08%
GM growth 3Y14.12%
GM growth 5Y2.16%
KMDA Yearly Profit, Operating, Gross MarginsKMDA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10 -10 20 30 40

6

2. Health

2.1 Basic Checks

With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), KMDA is destroying value.
The number of shares outstanding for KMDA has been increased compared to 1 year ago.
KMDA has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, KMDA has a worse debt to assets ratio.
KMDA Yearly Shares OutstandingKMDA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
KMDA Yearly Total Debt VS Total AssetsKMDA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

KMDA has an Altman-Z score of 3.30. This indicates that KMDA is financially healthy and has little risk of bankruptcy at the moment.
KMDA has a Altman-Z score of 3.30. This is in the better half of the industry: KMDA outperforms 69.06% of its industry peers.
KMDA has a debt to FCF ratio of 0.59. This is a very positive value and a sign of high solvency as it would only need 0.59 years to pay back of all of its debts.
KMDA has a Debt to FCF ratio of 0.59. This is amongst the best in the industry. KMDA outperforms 95.09% of its industry peers.
A Debt/Equity ratio of 0.04 indicates that KMDA is not too dependend on debt financing.
KMDA has a Debt to Equity ratio (0.04) which is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0.04
Debt/FCF 0.59
Altman-Z 3.3
ROIC/WACC0.78
WACC8.51%
KMDA Yearly LT Debt VS Equity VS FCFKMDA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M 100M 150M 200M 250M

2.3 Liquidity

A Current Ratio of 4.02 indicates that KMDA has no problem at all paying its short term obligations.
With a Current ratio value of 4.02, KMDA perfoms like the industry average, outperforming 48.11% of the companies in the same industry.
A Quick Ratio of 2.25 indicates that KMDA has no problem at all paying its short term obligations.
The Quick ratio of KMDA (2.25) is worse than 71.32% of its industry peers.
Industry RankSector Rank
Current Ratio 4.02
Quick Ratio 2.25
KMDA Yearly Current Assets VS Current LiabilitesKMDA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

6

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 28.57% over the past year.
Measured over the past years, KMDA shows a very negative growth in Earnings Per Share. The EPS has been decreasing by -13.60% on average per year.
The Revenue has grown by 10.36% in the past year. This is quite good.
KMDA shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 4.82% yearly.
EPS 1Y (TTM)28.57%
EPS 3YN/A
EPS 5Y-13.6%
EPS Q2Q%28.57%
Revenue 1Y (TTM)10.36%
Revenue growth 3Y15.82%
Revenue growth 5Y4.82%
Sales Q2Q%12.63%

3.2 Future

Based on estimates for the next years, KMDA will show a very strong growth in Earnings Per Share. The EPS will grow by 29.48% on average per year.
KMDA is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 10.31% yearly.
EPS Next Y44.17%
EPS Next 2Y31.88%
EPS Next 3Y29.48%
EPS Next 5YN/A
Revenue Next Year12.37%
Revenue Next 2Y11.55%
Revenue Next 3Y10.31%
Revenue Next 5YN/A

3.3 Evolution

When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
KMDA Yearly Revenue VS EstimatesKMDA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 50M 100M 150M 200M
KMDA Yearly EPS VS EstimatesKMDA Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 0.2 -0.2 0.4 -0.4

8

4. Valuation

4.1 Price/Earnings Ratio

Based on the Price/Earnings ratio of 19.64, the valuation of KMDA can be described as rather expensive.
Based on the Price/Earnings ratio, KMDA is valued cheaply inside the industry as 94.34% of the companies are valued more expensively.
KMDA is valuated rather cheaply when we compare the Price/Earnings ratio to 26.57, which is the current average of the S&P500 Index.
With a Price/Forward Earnings ratio of 15.63, KMDA is valued correctly.
KMDA's Price/Forward Earnings ratio is rather cheap when compared to the industry. KMDA is cheaper than 95.85% of the companies in the same industry.
KMDA is valuated rather cheaply when we compare the Price/Forward Earnings ratio to 24.04, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 19.64
Fwd PE 15.63
KMDA Price Earnings VS Forward Price EarningsKMDA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

97.36% of the companies in the same industry are more expensive than KMDA, based on the Enterprise Value to EBITDA ratio.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of KMDA indicates a rather cheap valuation: KMDA is cheaper than 95.09% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF 21.75
EV/EBITDA 8.06
KMDA Per share dataKMDA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 1 2 3 4

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
The decent profitability rating of KMDA may justify a higher PE ratio.
KMDA's earnings are expected to grow with 29.48% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.44
PEG (5Y)N/A
EPS Next 2Y31.88%
EPS Next 3Y29.48%

3

5. Dividend

5.1 Amount

KMDA has a Yearly Dividend Yield of 2.83%.
Compared to an average industry Dividend Yield of 1.01, KMDA pays a better dividend. On top of this KMDA pays more dividend than 98.68% of the companies listed in the same industry.
Compared to an average S&P500 Dividend Yield of 2.00, KMDA pays a bit more dividend than the S&P500 average.
Industry RankSector Rank
Dividend Yield 2.83%

5.2 History

KMDA is new to the dividend game and has less than 3 years of track record.
Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years0
KMDA Yearly Dividends per shareKMDA Yearly Dividends per shareYearly Dividends per share 2025 0.05 0.1 0.15

5.3 Sustainability

DPN/A
EPS Next 2Y31.88%
EPS Next 3Y29.48%
KMDA Yearly Income VS Free CF VS DividendKMDA Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M -10M 20M 30M

KAMADA LTD

NASDAQ:KMDA (12/26/2025, 8:00:02 PM)

7.07

-0.02 (-0.28%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-10 2025-11-10/bmo
Earnings (Next)03-03 2026-03-03/bmo
Inst Owners11.39%
Inst Owner Change3.21%
Ins Owners2.34%
Ins Owner ChangeN/A
Market Cap407.80M
Revenue(TTM)174.79M
Net Income(TTM)20.45M
Analysts84.44
Price Target13.26 (87.55%)
Short Float %0.14%
Short Ratio0.52
Dividend
Industry RankSector Rank
Dividend Yield 2.83%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-Date03-17 2025-03-17 (0.2)
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)20.52%
Min EPS beat(2)-4.61%
Max EPS beat(2)45.66%
EPS beat(4)3
Avg EPS beat(4)17.85%
Min EPS beat(4)-4.61%
Max EPS beat(4)45.66%
EPS beat(8)6
Avg EPS beat(8)19.32%
EPS beat(12)9
Avg EPS beat(12)7.95%
EPS beat(16)10
Avg EPS beat(16)-82.64%
Revenue beat(2)1
Avg Revenue beat(2)-0.44%
Min Revenue beat(2)-1.49%
Max Revenue beat(2)0.61%
Revenue beat(4)2
Avg Revenue beat(4)-0.44%
Min Revenue beat(4)-3.06%
Max Revenue beat(4)2.19%
Revenue beat(8)3
Avg Revenue beat(8)-0.6%
Revenue beat(12)4
Avg Revenue beat(12)-0.9%
Revenue beat(16)6
Avg Revenue beat(16)1.07%
PT rev (1m)-11.86%
PT rev (3m)-18.75%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-22.5%
EPS NY rev (1m)-3.92%
EPS NY rev (3m)-3.92%
Revenue NQ rev (1m)-0.38%
Revenue NQ rev (3m)-1.28%
Revenue NY rev (1m)0.27%
Revenue NY rev (3m)0.27%
Valuation
Industry RankSector Rank
PE 19.64
Fwd PE 15.63
P/S 2.33
P/FCF 21.75
P/OCF 14.06
P/B 1.54
P/tB 1.74
EV/EBITDA 8.06
EPS(TTM)0.36
EY5.09%
EPS(NY)0.45
Fwd EY6.4%
FCF(TTM)0.33
FCFY4.6%
OCF(TTM)0.5
OCFY7.11%
SpS3.03
BVpS4.59
TBVpS4.07
PEG (NY)0.44
PEG (5Y)N/A
Graham Number6.1
Profitability
Industry RankSector Rank
ROA 5.42%
ROE 7.72%
ROCE 8.44%
ROIC 6.67%
ROICexc 8.54%
ROICexgc 9.66%
OM 15.89%
PM (TTM) 11.7%
GM 43.75%
FCFM 10.73%
ROA(3y)1.79%
ROA(5y)2.56%
ROE(3y)2.5%
ROE(5y)3.16%
ROIC(3y)2.97%
ROIC(5y)N/A
ROICexc(3y)3.77%
ROICexc(5y)N/A
ROICexgc(3y)8.9%
ROICexgc(5y)N/A
ROCE(3y)3.76%
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5Y-12.21%
ROICexc growth 3YN/A
ROICexc growth 5Y-24.77%
OM growth 3YN/A
OM growth 5Y-7.07%
PM growth 3YN/A
PM growth 5Y-13.08%
GM growth 3Y14.12%
GM growth 5Y2.16%
F-Score7
Asset Turnover0.46
Health
Industry RankSector Rank
Debt/Equity 0.04
Debt/FCF 0.59
Debt/EBITDA 0.22
Cap/Depr 67.04%
Cap/Sales 5.86%
Interest Coverage 35.6
Cash Conversion 67.35%
Profit Quality 91.69%
Current Ratio 4.02
Quick Ratio 2.25
Altman-Z 3.3
F-Score7
WACC8.51%
ROIC/WACC0.78
Cap/Depr(3y)51.55%
Cap/Depr(5y)66.64%
Cap/Sales(3y)4.62%
Cap/Sales(5y)4.32%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)28.57%
EPS 3YN/A
EPS 5Y-13.6%
EPS Q2Q%28.57%
EPS Next Y44.17%
EPS Next 2Y31.88%
EPS Next 3Y29.48%
EPS Next 5YN/A
Revenue 1Y (TTM)10.36%
Revenue growth 3Y15.82%
Revenue growth 5Y4.82%
Sales Q2Q%12.63%
Revenue Next Year12.37%
Revenue Next 2Y11.55%
Revenue Next 3Y10.31%
Revenue Next 5YN/A
EBIT growth 1Y56.49%
EBIT growth 3YN/A
EBIT growth 5Y-2.59%
EBIT Next Year134.37%
EBIT Next 3Y44.92%
EBIT Next 5YN/A
FCF growth 1Y941.67%
FCF growth 3YN/A
FCF growth 5Y7.92%
OCF growth 1Y336.09%
OCF growth 3YN/A
OCF growth 5Y11.73%

KAMADA LTD / KMDA FAQ

Can you provide the ChartMill fundamental rating for KAMADA LTD?

ChartMill assigns a fundamental rating of 6 / 10 to KMDA.


Can you provide the valuation status for KAMADA LTD?

ChartMill assigns a valuation rating of 8 / 10 to KAMADA LTD (KMDA). This can be considered as Undervalued.


Can you provide the profitability details for KAMADA LTD?

KAMADA LTD (KMDA) has a profitability rating of 7 / 10.


Can you provide the financial health for KMDA stock?

The financial health rating of KAMADA LTD (KMDA) is 6 / 10.


Can you provide the expected EPS growth for KMDA stock?

The Earnings per Share (EPS) of KAMADA LTD (KMDA) is expected to grow by 44.17% in the next year.